<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04143152</url>
  </required_header>
  <id_info>
    <org_study_id>19021</org_study_id>
    <nct_id>NCT04143152</nct_id>
  </id_info>
  <brief_title>Pancreatic Cancer Biomarker Study</brief_title>
  <official_title>Evaluation of a Biomarker Panel for the Diagnosis and Prognosis of Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Van Andel Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Spectrum Health Hospitals</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mercy Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Van Andel Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a non-treatment, blood collection study to evaluate biomarker panels for the&#xD;
      diagnosis and prognosis of pancreatic cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a non-treatment, blood collection study to evaluate biomarker panels for the&#xD;
      diagnosis and prognosis of pancreatic cancer.&#xD;
&#xD;
      Study participants will be recruited by physician referral or from a list of clinical&#xD;
      patients being evaluated for a potential pancreatic abnormality or for potential treatment of&#xD;
      pancreatic cancer. Additionally, a surveillance cohort will be recruited among individuals&#xD;
      who are being monitored for recurrence following surgical or medical treatment for pancreatic&#xD;
      cancer.&#xD;
&#xD;
      Peripheral blood specimens will be collected from all participants at time of enrollment.&#xD;
      Additional specimens may be collected from surveillance cohort participants no more&#xD;
      frequently than once every 3 months as clinically indicated.&#xD;
&#xD;
      The specimens will be sent to a clinical lab for sTRA biomarker and CA19-9 analysis.&#xD;
      Participants will be followed for 36 months to track clinical outcomes. The performance of&#xD;
      the investigation biomarker for the diagnosis, prognosis, or surveillance of pancreatic&#xD;
      cancer will be compared to the performance of CA19-9.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2021</start_date>
  <completion_date type="Anticipated">October 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnosis of adenocarcinoma of the pancreas</measure>
    <time_frame>Up to three years</time_frame>
    <description>Number of patients clinically diagnosed with pancreatic adenocarcinoma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Investigational biomarker panel for diagnosis</measure>
    <time_frame>Enrollment</time_frame>
    <description>sTRA biomarker and CA 19-9 levels at enrollment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease progression</measure>
    <time_frame>Up to three years</time_frame>
    <description>Disease progression of pancreatic adenocarcinoma as measured by RESIST v1.1 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigational biomarker panel for disease surveillance</measure>
    <time_frame>Up to three years</time_frame>
    <description>sTRA biomarker and CA 19-9 levels measured at any time point deemed clinically relevant for standard of care.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Pancreatic Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Diagnostic/prognostic cohort</arm_group_label>
    <description>Patients being evaluated for a potential pancreatic abnormality or for potential treatment for pancreatic adenocarcinoma.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Surveillance Cohort</arm_group_label>
    <description>Patients who are being monitored for recurrence following surgical or medical treatment for pancreatic adenocarcinoma</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Peripheral blood specimens&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Participants will be recruited from collaborating clinical sites by screening physician&#xD;
        schedules and through physician referral.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Diagnosis/Prognosis Cohort&#xD;
&#xD;
          -  Patients being evaluated for possible pancreatic abnormality, via additional&#xD;
             radiological test (endoscopic ultrasound, abdominal CT scan), blood test (CA19-9), or&#xD;
             other diagnostic procedure.&#xD;
&#xD;
          -  Patients being evaluated for medical or surgical treatment for pancreatic cancer or&#xD;
             pancreatitis on the basis of previous clinical and radiological findings.&#xD;
&#xD;
        Surveillance Cohort&#xD;
&#xD;
          -  Patients being monitored or who will be monitored for potential recurrence of&#xD;
             pancreatic cancer following surgical or medical treatment of pancreatic&#xD;
             adenocarcinoma.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The participant is unwilling or unable to provide written informed consent.&#xD;
&#xD;
          -  In the investigator's opinion, the participant is unsuitable for the study.&#xD;
&#xD;
          -  The participant does not speak English.&#xD;
&#xD;
          -  The participant is a prisoner.&#xD;
&#xD;
          -  The participant is known to be pregnant.&#xD;
&#xD;
          -  The participant is less than 18 years of age.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian Haab, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Van Andel Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Brian Haab, PhD</last_name>
    <phone>616-234-5268</phone>
    <email>brian.haab@vai.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mercy Health Saint Mary's Hospital</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pamela Bartlett, BS</last_name>
      <phone>616-685-5252</phone>
      <email>bartletp@mercyhealth.com</email>
    </contact>
    <investigator>
      <last_name>J. Bradley Morrow, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Staal B, Liu Y, Barnett D, Hsueh P, He Z, Gao C, Partyka K, Hurd MW, Singhi AD, Drake RR, Huang Y, Maitra A, Brand RE, Haab BB. The sTRA Plasma Biomarker: Blinded Validation of Improved Accuracy Over CA19-9 in Pancreatic Cancer Diagnosis. Clin Cancer Res. 2019 May 1;25(9):2745-2754. doi: 10.1158/1078-0432.CCR-18-3310. Epub 2019 Jan 7.</citation>
    <PMID>30617132</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>October 16, 2019</study_first_submitted>
  <study_first_submitted_qc>October 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2019</study_first_posted>
  <last_update_submitted>April 20, 2021</last_update_submitted>
  <last_update_submitted_qc>April 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

